Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia
Аутори
Stojanović, Marijana M.Lukić, Ivana
Marinković, Emilija
Kovačević, Ana
Miljković, Radmila
Tobias, Joshua
Schabussova, Irma
Zlatović, Mario
Barisani-Asenbauer, Talin
Wiedermann, Ursula
Inic-Kanada, Aleksandra
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Vaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydiacaviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred ≈40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology inte...nsity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen.
Кључне речи:
antibodies / Chlamydia / cross-reactivity / heterologous immunity / tetanus / vaccinationИзвор:
Vaccines, 2020, 8, 4, 719-Финансирање / пројекти:
- This work was institutionally funded by the Institute for Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Austria, and partially supported by the Austrian Research Promotion Agency (FFG project number 822768).
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200177 (Центар за имунолошка истраживања 'Бранислав Јанковић' Торлак, Београд) (RS-200177)
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200168 (Универзитет у Београду, Хемијски факултет) (RS-200168)
DOI: 10.3390/vaccines8040719
ISSN: 2076-393X
WoS: 000601709900001
Scopus: 2-s2.0-85097255732
Колекције
Институција/група
Hemijski fakultet / Faculty of ChemistryTY - JOUR AU - Stojanović, Marijana M. AU - Lukić, Ivana AU - Marinković, Emilija AU - Kovačević, Ana AU - Miljković, Radmila AU - Tobias, Joshua AU - Schabussova, Irma AU - Zlatović, Mario AU - Barisani-Asenbauer, Talin AU - Wiedermann, Ursula AU - Inic-Kanada, Aleksandra PY - 2020 UR - https://cherry.chem.bg.ac.rs/handle/123456789/4292 AB - Vaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydiacaviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred ≈40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology intensity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen. T2 - Vaccines T1 - Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia VL - 8 IS - 4 SP - 719 DO - 10.3390/vaccines8040719 ER -
@article{ author = "Stojanović, Marijana M. and Lukić, Ivana and Marinković, Emilija and Kovačević, Ana and Miljković, Radmila and Tobias, Joshua and Schabussova, Irma and Zlatović, Mario and Barisani-Asenbauer, Talin and Wiedermann, Ursula and Inic-Kanada, Aleksandra", year = "2020", abstract = "Vaccines can have heterologous effects on the immune system, i.e., effects other than triggering an immune response against the disease targeted by the vaccine. We investigated whether monoclonal antibodies (mAbs) specific for tetanus could cross-react with Chlamydia and confer heterologous protection against chlamydial infection. The capability of two tetanus-specific mAbs, namely mAb26 and mAb51, to prevent chlamydial infection has been assessed: (i) in vitro, by performing a neutralization assay using human conjunctival epithelial (HCjE) cells infected with Chlamydia trachomatis serovar B, and (ii) in vivo, by using a guinea pig model of Chlamydiacaviae-induced inclusion conjunctivitis. The mAb26 has been superior in comparison with mAb51 in the prevention of chlamydial infection in HCjE cells. The mAb26 has conferred ≈40% inhibition of the infection, compared to less than 5% inhibition in the presence of the mAb51. In vivo, mAb26 significantly diminished ocular pathology intensity in guinea pigs infected with C. caviae compared to either the mAb51-treated or sham-treated guinea pigs. Our data provide insights that tetanus immunization generates antibodies which induce heterologous chlamydial immunity and promote protection beyond the intended target pathogen.", journal = "Vaccines", title = "Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia", volume = "8", number = "4", pages = "719", doi = "10.3390/vaccines8040719" }
Stojanović, M. M., Lukić, I., Marinković, E., Kovačević, A., Miljković, R., Tobias, J., Schabussova, I., Zlatović, M., Barisani-Asenbauer, T., Wiedermann, U.,& Inic-Kanada, A.. (2020). Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. in Vaccines, 8(4), 719. https://doi.org/10.3390/vaccines8040719
Stojanović MM, Lukić I, Marinković E, Kovačević A, Miljković R, Tobias J, Schabussova I, Zlatović M, Barisani-Asenbauer T, Wiedermann U, Inic-Kanada A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. in Vaccines. 2020;8(4):719. doi:10.3390/vaccines8040719 .
Stojanović, Marijana M., Lukić, Ivana, Marinković, Emilija, Kovačević, Ana, Miljković, Radmila, Tobias, Joshua, Schabussova, Irma, Zlatović, Mario, Barisani-Asenbauer, Talin, Wiedermann, Ursula, Inic-Kanada, Aleksandra, "Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia" in Vaccines, 8, no. 4 (2020):719, https://doi.org/10.3390/vaccines8040719 . .